Baxter International (NYSE:BAX) Issues FY 2025 Earnings Guidance

Key Points

• Baxter International has updated its FY 2025 earnings guidance, projecting earnings per share (EPS) of 2.420-2.520 and revenues of $11.3 billion to $11.4 billion, closely in line with consensus estimates.
• The company's stock has experienced an 18.0% decline recently, with analysts providing mixed ratings and target price adjustments.
• Baxter International announced a quarterly dividend payout of $0.17, leading to an annualized yield of 2.96%, with the ex-dividend date set for August 29th.

Baxter International (NYSE:BAX - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 2.420-2.520 for the period, compared to the consensus earnings per share estimate of 2.517. The company issued revenue guidance of $11.3 billion-$11.4 billion, compared to the consensus revenue estimate of $11.4 billion. Baxter International also updated its Q3 2025 guidance to 0.580-0.620 EPS.

Wall Street Analyst Weigh In

BAX has been the subject of several analyst reports. The Goldman Sachs Group lowered Baxter International from a "buy" rating to a "neutral" rating and set a $25.00 price objective for the company. in a research note on Friday. Wall Street Zen cut shares of Baxter International from a "buy" rating to a "hold" rating in a research report on Saturday. Citigroup dropped their price target on shares of Baxter International from $34.00 to $32.00 and set a "neutral" rating for the company in a research note on Wednesday, July 9th. Morgan Stanley reduced their price objective on shares of Baxter International from $28.00 to $27.00 and set an "underweight" rating on the stock in a research report on Tuesday, July 15th. Finally, Evercore ISI dropped their target price on Baxter International from $44.00 to $42.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $33.13.

Baxter International Trading Up 1.0%

Shares of NYSE:BAX traded up $0.21 during trading on Friday, reaching $21.97. 22,646,910 shares of the company were exchanged, compared to its average volume of 7,544,769. The business's fifty day simple moving average is $29.52 and its 200-day simple moving average is $31.03. The company has a debt-to-equity ratio of 1.33, a current ratio of 2.02 and a quick ratio of 1.40. Baxter International has a 12-month low of $21.33 and a 12-month high of $40.49. The firm has a market capitalization of $11.27 billion, a PE ratio of -73.23, a P/E/G ratio of 0.65 and a beta of 0.59.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical instruments supplier reported $0.59 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.01). The firm had revenue of $2.81 billion for the quarter, compared to analysts' expectations of $2.82 billion. Baxter International had a positive return on equity of 16.93% and a negative net margin of 1.42%. The company's revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.68 earnings per share. On average, research analysts anticipate that Baxter International will post 2.48 EPS for the current year.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Friday, August 29th will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, August 29th. Baxter International's dividend payout ratio is presently -226.67%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.